Glycemic Control Influences Serum Angiogenin Concentrations in Patients With Type 2 Diabetes

Janusz Siebert, MD, PhD1
Magdalena Reiwer-Gostomská, MD1
Jolanta Mysińska, MD, PhD2
Natalia Marek, PhD2
Krzystyna Raczyńska, MD, PhD3
Leopold Glawsner, MD3

OBJECTIVE — Because diabetes is the most frequent factor responsible for microvascular and macrovascular disease, we investigated angiogenin serum levels within the diabetic patient group.

RESEARCH DESIGN AND METHODS — We investigated 49 patients who met the criteria to be in the diabetic group. Forty nondiabetic patients were included in the control group. We set A1C <7% as well-controlled diabetes. Serum angiogenin level was measured using the enzyme-linked immunosorbent assay method.

RESULTS — Serum angiogenin levels of poorly controlled patients with type 2 diabetes were significantly lower than those of group with well-controlled diabetes (361.23 ± 126.03 mg/ml vs. 446.37 ± 134.10 mg/ml; P = 0.001). Moreover, they were characterized by a significantly longer duration of the disease (P = 0.006), higher BMI (P = 0.0003), and higher systolic blood pressure (P = 0.01). Levels of total cholesterol, triglycerides, LDL, and HDL were not significantly different in both groups.

CONCLUSIONS — Patients with poorly controlled type 2 diabetes (A1C >7%) have lower angiogenin levels than patients with well-controlled diabetes.

Diabetes Care 33:1829–1830, 2010

Diabetes is associated with angiopathy, which increases the risk of a variety of complications. To minimize the degree of ischemic damage, collateral vessels of the large arteries are developed. This process is, unfortunately, insufficient in diabetic patients, leading to a three- to fourfold increase in mortality risk. Both coronary vessel formation and capillary density are poorer in patients with diabetes than in a healthy control group (1,2).

Angiogenesis is a complex process regulated by stimulatory and inhibitory factors. It is well established in research that the expression of different angiogenic growth factors are reduced in diabetes. On the other hand, diabetic patients with coronary artery disease exhibit higher levels of angiotatin and endostatin (3). In the meantime, the molecular angiogenic signaling pathways influencing coronary collateral formation remain poorly understood.

We have previously demonstrated that the serum level of one of the angiogenic growth factors, namely angiogenin, is reduced in diabetes (4). The present investigation was designed to test the hypothesis that the serum level of angiogenin depends on glucose concentration control.

RESEARCH DESIGN AND METHODS — A total of 49 consecutive patients with type 2 diabetes from the Department of Family Medicine, Medical University of Gdańsk, admitted to the Department of Ophthalmology for a routine control were recruited between September and December 2009. They were divided into two groups according to the level of A1C (18 subjects with A1C <7% and 31 subjects with A1C ≥7%). Patients suffering from acute and chronic infections and neoplastic diseases were excluded. Diabetes was defined according to the American Diabetes Association criteria (5). All patients had blood glucose >7 mmol/l, and we set A1C <7% as well-controlled diabetes. Serum angiogenin levels were measured twice with the ELISA Quantkine kit (R&D Systems, Minneapolis, MN). A1C was evaluated by the immunoturbidimetric method using the Unimate 3 set (Hoffman-La Roche, Basel, Switzerland). A group of 40 healthy age- and sex-matched individuals was used as a control. They remained under continuous supervision at The Family Medicine Outpatient Clinic.

The results were analyzed using Statistica software, version 8 (Stat Soft Polska). The level of significance was set at P < 0.05. Student t and the Kruskal-Wallis ANOVA tests were performed as standard.

RESULTS — Serum angiogenin levels of poorly controlled patients with type 2 diabetes were significantly lower than those of the group with well-controlled diabetes (P = 0.001). Moreover, they were characterized by a significantly longer duration of the disease and higher BMI and systolic blood pressure. Levels of total cholesterol, triglycerides, LDL, and HDL were not significantly different from those of the well-controlled patients (Table 1).

The patients with A1C >7% suffered significantly more often from hypertension (P = 0.003) and ischemic heart disease (P = 0.004). However, there was no significant difference in the occurrence of late complications of diabetes.

There were significant differences between treatment regimes. The well-controlled patients received sulfonylurea significantly more often (P = 0.0007), while the poorly controlled group was treated mainly with insulin (P = 0.002). No significant differences in statin and ACE inhibitor treatment were observed.

The serum angiogenin level of the healthy control group was significantly higher than that of the total diabetic pa-
Angiogenin is an important and still poorly investigated angiogenic growth factor (10) that has a great influence on the process of creation of new vessels. When introduced into Balb/c mice in a serum-induced angiogenesis test, the serum angiogenin of diabetic patients causes a significant decrease in new vessel formation (4).

The present results confirm the findings of our previous studies and indicate the correlation between the glycemic control and the inhibition of the serum angiogenin level. We discovered that the serum angiogenin level is markedly decreased in patients with A1C < 7% (472.57 ± 146.30 ng/ml) vs. 392.5 ± 134.2 ng/ml; P = 0.000017). ANOVA and post hoc NIR Fisher test detected significant differences between healthy subjects and patients with A1C > 7% (472.57 ± 146.30 ng/ml vs. 361.23 ± 126.03 ng/ml; P = 0.00002) and within the two diabetic groups P = 0.03.

### CONCLUSIONS — The rising prevalence of diabetes is leading to a significant increase in long-term diabetes complications such as retinopathy, nephropathy, neuropathy, and ischemic heart disease, which have a considerable impact on the patients (6). The data available on the effect of hyperglycemia on the process of angiogenesis are still limited. Numerous authors have suggested that a high concentration of glucose causes endothelial cell dysfunction (7,8). Weihrauch et al. (9) indicated that the production of inhibitors of angiogenesis is an important mechanism for the impairment of collateral development observed during hyperglycemia.

Angiogenin is an important and still poorly investigated angiogenic growth factor (10) that has a great influence on the process of creation of new vessels. When introduced into Balb/c mice in a serum-induced angiogenesis test, the serum angiogenin of diabetic patients causes a significant decrease in new vessel formation (4).

The present results confirm the findings of our previous studies and indicate the correlation between the glycemic control and the inhibition of the serum angiogenin level. We discovered that the serum angiogenin level is markedly decreased in patients with A1C > 7% (472.57 ± 146.30 ng/ml) vs. 392.5 ± 134.2 ng/ml; P = 0.000017). ANOVA and post hoc NIR Fisher test detected significant differences between healthy subjects and patients with A1C > 7% (472.57 ± 146.30 ng/ml vs. 361.23 ± 126.03 ng/ml; P = 0.00002) and within the two diabetic groups P = 0.03.

### Acknowledgments — No potential conflicts of interest relevant to this article were reported.

|Parameter| A1C < 7%| A1C ≥ 7%| P value |
|---|---|---|---|
|n| 18| 31| |
|Age (years)| 66.22 ± 12.34| 66.29 ± 8.91| 0.8436|
|Weight (kg)| 75.18 ± 12.73| 86.82 ± 16.15| 0.0127|
|BMI (kg/m²)| 26.56 ± 3.37| 32.05 ± 6.07| 0.0003|
|Systolic blood pressure (mmHg)| 130.53 ± 12.76| 142.77 ± 16.87| 0.0127|
|Diastolic blood pressure (mmHg)| 72.41 ± 18.00| 79.30 ± 9.26| 0.1054|
|Diabetes duration (years)| 7.12 ± 5.93| 12.33 ± 6.33| 0.0068|
|A1C (%)| 6.17 ± 0.44| 8.69 ± 1.40| 0.000001|
|Angiogenin (ng/ml)| 446.37 ± 134.10| 361.23 ± 126.03| 0.0308|
|Total cholesterol (mmol/l)| 195.18 ± 29.25| 212.07 ± 38.09| 0.1263|
|LDL cholesterol (mmol/l)| 118.81 ± 23.85| 127.48 ± 35.80| 0.3948|
|HDL cholesterol (mmol/l)| 45.82 ± 11.04| 51.59 ± 20.23| 0.3.467|
|Triglycerides (mmol/l)| 145.56 ± 68.53| 167.11 ± 64.20| 0.3055|
|Hypertension (%)| 66.67| 96.77| 0.0037|
|Nephropathy (%)| 5.56| 6.45| 0.8996|
|Retinopathy (%)| 17.65| 30.00| 0.3507|
|Foot ulceration (%)| 11.11| 16.13| 0.6285|
|Ischemic heart disease (%)| 11.11| 51.61| 0.0046|
|ACE inhibitor (%)| 52.94| 80.00| 0.0513|
|Statins (%)| 29.41| 51.72| 0.1406|
|Sulphonylurea (%)| 84.62| 11.11| 0.0007|
|Metformin (%)| 53.85| 22.22| 0.1380|
|Insulin (%)| 23.08| 68.89| 0.0024|

Data are arithmetic means ± SD or percentage of patients.

### References

1. Abaci A, Oguzhan A, Kahraman S, Eryol NK, UnalS, Arinc H, Egrin A. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999;99:2239–2242
2. Schiekoler S, Gallasso G, Sato K, Kraus BJ, Walsh K. Impaired revascularisation in a mouse model of type 2 diabetes is associated with dysregulation of complex angiogenic-regulatory network. Arterioscler Thromb Vasc Biol 2005;25:1603–1609
3. Sodha NR, Clements RT, Boodhwani M, Xu SH, Laham RJ, Bianchi C, Sellke FW. Endostatin and angiotatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Am J Physiol Heart Circ Physiol 2009;296:H428–H434
4. Siebert J, Reiwant-Gostomska M, Babinska Z, Mysliwska J, Mysliwski A, Skopinska – Rozewska E, Sommer E, Skopinski P. Low serum angiogenin level concentrations in patients with type 2 diabetes. Diabetes Care 2007;30:12:3086–3087
5. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005;28(Suppl. 1):S37–S47
6. Ma J, Zhang SX, Wang JJ. Down-regulation of angiogenic inhibitors: a potential pathogenic mechanism for diabetic complications. Current Diabetes Reviews 2005;1:183–196
7. Waltenberger J. VEGF resistance as a molecular basis to explain the angiogenesis paradox in diabetes mellitus. Biochem Soc Trans 2009;37:1167–1170
8. Jessani S, Millane T, Lip GY. Vascular damage in impaired glucose tolerance: an unappreciated phenomenon? Curr Pharm Des 2009;15(29):3417–3432
9. Weihrauch D, Lohr NL, Mraovic B, Ludwig DM, Chilian WM, Pagel PS, Warltier DC, Kersten JR. Chronic hyperglycemia attenuates coronary collateral development and impairs proliferative properties of myocardial interstitial fluid by production of angiotatin. Circulation 2004;109:2343–2348
10. Hu G, Rorriand JF, Vallee BL. Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci USA 1994;91:12096–12100
11. Straaton IM, Adler AI, Neil HAW, Mathews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–412